Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants
Bhagchandani S, Johnson J, Irvine D. Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants. Advanced Drug Delivery Reviews 2021, 175: 113803. PMID: 34058283, PMCID: PMC9003539, DOI: 10.1016/j.addr.2021.05.013.Peer-Reviewed Original ResearchConceptsVaccine adjuvantsImidazoquinoline derivativesToll-like receptor 7Candidate vaccine adjuvantsSkin cancer treatmentBroad therapeutic utilityTLR7 toleranceTopical antiviralsImmunomodulatory agentsReceptor 7Systemic administrationPoor pharmacokinetic propertiesTherapeutic utilitySuccessful clinical translationSynthetic agonistsAntiviral formulationsInfectious diseasesPharmacokinetic propertiesCancer treatmentBroad expression profileAdjuvantClinical translationBiodistributionExpression profilesTherapeutics
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply